Cancel

Links to sites outside of njzhgg.com are provided as a resource to the audiences. Please note that Takeda is not responsible or liable for any third-party website and the website may not be appropriate for all audiences. 

To stay on the current website, select “Cancel”


Continue

You are leaving Takeda.com

Takeda - Global

EPD-3055 OneTrust Cookie

EPD-3519 Schema Script

EPD-2855 GTM Script

EPD-4037 Matomo Tag Manager

EPD-4268 Cookie Script Hack

Our vision is to restore life to living for patients suffering from gastrointestinal (GI) and inflammatory diseases by delivering innovative, life-changing therapeutics. 

Therapeutic Focus - Gastrointestinal and Inflammation | Takeda Pharmaceuticals

Divider Section

Our vision is to restore life to living for patients suffering from gastrointestinal (GI) and inflammatory diseases by delivering innovative, life-changing therapeutics. With over 30 years of experience in gastroenterology and a strategy to expand on our core expertise in inflammation, we are developing treatments in areas of high unmet need including inflammatory bowel disease, celiac disease, psoriasis, advanced liver disease, and neurogastric disorders.

To make a real difference, we must understand how GI and inflammatory diseases impact the everyday lives of patients. Routines are interrupted, symptom management takes precedence, and embarrassment can make the emotional pain just as present as the physical. Our approach is a simple one:  we work where the needs of patients intersect with promising science.

Together with researchers, patient groups and other partners, we are working to advance scientific research and clinical medicine to improve disease management for all those affected by GI and inflammatory diseases.


*   **Inflammatory Bowel Disease (IBD):** includes IBD (ulcerative colitis and Crohn’s disease) and associated complications such as perianal fistulas, short bowel syndrome and intestinal failure.

*   **Celiac Disease:** complements our efforts in IBD as another GI inflammatory disease. Our aim is to deliver  disease-modifying treatments by targeting a range of mechanisms including immune response, tolerance, and protein degradation.

*   **Dermatological & Rheumatic Diseases:** focus on inflammatory diseases such as psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE) and the exploration of additional immune-mediated diseases.

*   **Liver Diseases:** focus on three distinct areas: select rare monogenic liver diseases, fibrosis in chronic liver diseases such as nonalcoholic steatohepatitis (NASH) and select end-stage liver diseases.

*   **Neurogastric Disorders:** encompass a diverse range of diseases including gastroparesis and cyclic vomiting syndrome.

